NEW YORK (GenomeWeb) – Munich Leukemia Laboratory (MLL) has begun a collaboration with IBM and Illumina to develop a new cognitive technology prototype for providing personalized leukemia and lymphoma treatments.
The project will use IBM’s Watson and MLL will be the first European adopter of the Illumina high-throughput sequencing NovaSeq platform.
Get the full story This story is free
for registered users
Registering provides access to this and other free content.
Already have an account?